The Colorectal Cancer Landscape
Incidence of Colorectal Cancer continues to rise, with the disease now ranked 3rd for prevalence amongst cancer indications and cases predicted to increase by 63% by 2040.
With exclusive data from Beacon, this report contains:
- Analysis of Colorectal Cancer assets advancing towards late-phase clinical trials
- Insights into promising novel targets across all drug modalities
- Overview of recent approvals in the Colorectal Cancer treatment landscape
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
